Publication:
Pitfalls in estimating piperaquine elimination

Simple item page
dc.contributor.authorJoel Tarningen_US
dc.contributor.authorNiklas Lindegårdhen_US
dc.contributor.authorAnna Annerbergen_US
dc.contributor.authorThida Singtorojen_US
dc.contributor.authorNicholas P.J. Dayen_US
dc.contributor.authorMichael Ashtonen_US
dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.otherGoteborg University, Sahlgrenska Academyen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-06-21T08:20:11Z
dc.date.available2018-06-21T08:20:11Z
dc.date.issued2005-12-01en_US
dc.description.abstractBy using a sensitive new assay, the terminal elimination half-life of the antimalarial piperaquine in a healthy volunteer was estimated to be 33 days, which is longer than estimated previously. This result illustrates the importance of extended sampling duration and sensitive assay methodologies in characterizing the disposition of slowly eliminated antimalarial drugs. Copyright © 2005, American Society for Microbiology. All Rights Reserved.en_US
dc.identifier.citationAntimicrobial Agents and Chemotherapy. Vol.49, No.12 (2005), 5127-5128en_US
dc.identifier.doi10.1128/AAC.49.12.5127-5128.2005en_US
dc.identifier.issn00664804en_US
dc.identifier.other2-s2.0-28844503112en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/16719
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=28844503112&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titlePitfalls in estimating piperaquine eliminationen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=28844503112&origin=inwarden_US

Files

Collections

Scopus 2001-2005